Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to -$27.9 million.

  • Voyager Therapeutics' Consolidated Net Income fell 20840.34% to -$27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$126.8 million, marking a year-over-year decrease of 58988.41%. This contributed to the annual value of -$65.0 million for FY2024, which is 14912.11% down from last year.
  • Voyager Therapeutics' Consolidated Net Income amounted to -$27.9 million in Q3 2025, which was down 20840.34% from -$33.4 million recorded in Q2 2025.
  • Voyager Therapeutics' Consolidated Net Income's 5-year high stood at $124.0 million during Q1 2023, with a 5-year trough of -$34.5 million in Q4 2024.
  • Over the past 5 years, Voyager Therapeutics' median Consolidated Net Income value was -$22.2 million (recorded in 2023), while the average stood at -$7.7 million.
  • In the last 5 years, Voyager Therapeutics' Consolidated Net Income tumbled by 56669.3% in 2022 and then surged by 68184.72% in 2023.
  • Quarter analysis of 5 years shows Voyager Therapeutics' Consolidated Net Income stood at $5.1 million in 2021, then crashed by 566.69% to -$23.6 million in 2022, then surged by 338.86% to $56.4 million in 2023, then tumbled by 161.15% to -$34.5 million in 2024, then grew by 19.12% to -$27.9 million in 2025.
  • Its Consolidated Net Income was -$27.9 million in Q3 2025, compared to -$33.4 million in Q2 2025 and -$31.0 million in Q1 2025.